Tinlarebant + Placebo

Phase 2/3Active

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

STGD1

Conditions

STGD1, Stargardt Disease 1

Trial Timeline

Jul 31, 2024 → Feb 1, 2028

NCT ID

NCT06388083

About Tinlarebant + Placebo

Tinlarebant + Placebo is a phase 2/3 stage product being developed by Belite Bio for STGD1. The current trial status is active. This product is registered under clinical trial identifier NCT06388083. Target conditions include STGD1, Stargardt Disease 1.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06388083	Phase 2/3	Active	Jul 31, 2024	Feb 1, 2028	STGD1
NCT05949593	Phase 3	Active	Jul 27, 2023	Aug 31, 2027	Geographic Atrophy
NCT05244304	Phase 3	Completed	Mar 28, 2022	Sep 12, 2025	Stargardt Disease 1

Other Products from Belite Bio

Tinlarebant + PlaceboPhase 3

tinlarebantPhase 1/2

BPN-14967 + PlaceboPhase 1

Tinlarebant (LBS-008)Phase 1